Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up
No Thumbnail Available
Date
2018-01-01
Journal Title
Journal ISSN
Volume Title
Publisher
TAYLOR \& FRANCIS LTD
Abstract
Objectives: This report presents final results (24 months of follow-up) from the first prospective, national study of frontline nilotinib in chronic myeloid leukemia (CML) patients in Turkey. Methods: Patients with newly diagnosed Philadelphia chromosome-positive CML in chronic phase (CML-CP
N = 112) received nilotinib 300 mg twice daily. The primary endpoint, which was the cumulative rate of major molecular response (MMR
BCR-ABL1 <= 0.1\% on the International Scale {[}BCR-ABL1(IS)]) by 12 months, was previously reported (66.1\% {[}80\% CI, 59.7\%-72.0\%]). ClinicalTrials.gov identifier NCT01274351 Results: By 24 months, 83.0\% of patients achieved MMR, and 50.9\% achieved MR4.5 (BCR-ABL1(IS) <= 0.0032\%). Safety results at 24 months were consistent with those at 12 months. No additional deaths or disease progressions to accelerated phase/blast crisis were observed between 12 and 24 months. Discussion: Treatment with nilotinib 300 mg twice daily for 2 years provided high MMR with a good safety/tolerability profile in newly diagnosed CML-CP patients in Turkey. Assessment of MMR across time points showed increasing rates through 18 months, after which as lower rate of increase was observed. The safety profile of nilotinib 300 mg twice daily with 24 months of follow-up was similar to that observed at 12 months, and no new safety concerns were identified. These efficacy and safety findings are consistent with the results from the 12-month analysis of this study and from previous nilotinib studies. These findings support nilotinib as an option for frontline treatment of CML-CP. Conclusion: Frontline nilotinib treatment provided sustained efficacy, with good tolerability, over 24 months in newly diagnosed CML-CP patients.
N = 112) received nilotinib 300 mg twice daily. The primary endpoint, which was the cumulative rate of major molecular response (MMR
BCR-ABL1 <= 0.1\% on the International Scale {[}BCR-ABL1(IS)]) by 12 months, was previously reported (66.1\% {[}80\% CI, 59.7\%-72.0\%]). ClinicalTrials.gov identifier NCT01274351 Results: By 24 months, 83.0\% of patients achieved MMR, and 50.9\% achieved MR4.5 (BCR-ABL1(IS) <= 0.0032\%). Safety results at 24 months were consistent with those at 12 months. No additional deaths or disease progressions to accelerated phase/blast crisis were observed between 12 and 24 months. Discussion: Treatment with nilotinib 300 mg twice daily for 2 years provided high MMR with a good safety/tolerability profile in newly diagnosed CML-CP patients in Turkey. Assessment of MMR across time points showed increasing rates through 18 months, after which as lower rate of increase was observed. The safety profile of nilotinib 300 mg twice daily with 24 months of follow-up was similar to that observed at 12 months, and no new safety concerns were identified. These efficacy and safety findings are consistent with the results from the 12-month analysis of this study and from previous nilotinib studies. These findings support nilotinib as an option for frontline treatment of CML-CP. Conclusion: Frontline nilotinib treatment provided sustained efficacy, with good tolerability, over 24 months in newly diagnosed CML-CP patients.
Description
Keywords
BCR-ABL1, chronic myeloid leukemia, molecular response, nilotinib, tyrosine kinase inhibitor